Baibys Secures $4.5M in Series A Funding for AI-Powered Fertility Solutions
Baibys aims to improve fertility outcomes with a state-of-the-art AI platform that not only evaluates but also selects optimal sperm cells, ensuring higher quality and efficiency in fertility treatments.
Company Name: Baibys
Location: Tel Aviv, Israel
Sector: Healthcare, AI, Fertility Technology
Funding Details: Raised $4.5 million in Series A funding led by Firstime Ventures, with participation from ROHTO.
Purpose of Investment: To expand operations, enhance development efforts, and extend business reach.
Leadership: Chaired by Itay Itzhaky, with Dr. Yaron Silberman serving as CEO. Co-founders include Gal Golov (Co-CEO) and Dr. Nino Guy Cassuto (Chief Medical Officer). The team also includes Nahum Budin as Sr. VP of R&D and David Rigler as VP of Regulatory, Clinical, & Quality Affairs.
Product and Innovation: Baibys has developed an innovative autonomous sperm selection system for In-Vitro Fertilization (IVF) using Machine Vision (MV) and Artificial Intelligence (AI). This system analyzes living sperm cells in real-time, evaluates them based on morphological criteria via high magnification, and autonomously selects sperm with the highest fertilization potential for IVF procedures.
Company Growth: Focused on revolutionizing the fertility industry by enhancing the precision and effectiveness of IVF treatments through advanced AI technologies.
About the Company: Baibys aims to improve fertility outcomes with a state-of-the-art AI platform that not only evaluates but also selects optimal sperm cells, ensuring higher quality and efficiency in fertility treatments. The team's expertise combines technological innovation with deep medical insights to push the boundaries of reproductive health services.
